BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38353396)

  • 21. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
    Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
    Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
    Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
    Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
    Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
    Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
    Fu T; Yang Y; Mu Z; Sun R; Li X; Dong J
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):680-692. PubMed ID: 34435542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
    Yu Y; Wang A; Wang S; Sun Y; Chu L; Zhou L; Yang X; Liu X; Sha C; Sun K; Xu L
    Mol Pharm; 2022 Apr; 19(4):1219-1229. PubMed ID: 35262365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interplay of m
    Li F; Chen S; Yu J; Gao Z; Sun Z; Yi Y; Long T; Zhang C; Li Y; Pan Y; Qin C; Long W; Liu Q; Zhao W
    Clin Transl Med; 2021 Sep; 11(9):e553. PubMed ID: 34586728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.
    Yang JT; Lee IN; Huang C; Huang HC; Wu YP; Chong ZY; Chen JC
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
    Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
    ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
    Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
    BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2-HO-1 Axis.
    Chuang HY; Hsu LY; Pan CM; Pikatan NW; Yadav VK; Fong IH; Chen CH; Yeh CT; Chiu SC
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neovascularization directed by CAVIN1/CCBE1/VEGFC confers TMZ-resistance in glioblastoma.
    Wang M; Xia D; Xu D; Yin Y; Xu F; Zhang B; Li K; Yang Z; Zou J
    Cancer Lett; 2024 Feb; 582():216593. PubMed ID: 38092144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
    Wang S; Chen C; Li J; Xu X; Chen W; Li F
    J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
    J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
    Wang F; Xu L; Wen B; Song S; Zhou Y; Wu H; Wu Q; Wang Y; Tong X; Yan H
    Cancer Lett; 2023 Feb; 554():216033. PubMed ID: 36493901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
    Li XD; Wang MJ; Zheng JL; Wu YH; Wang X; Jiang XB
    Cancer Sci; 2021 Nov; 112(11):4543-4552. PubMed ID: 34390075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo.
    Radin DP; Shifman S; Outhwaite IR; Sharma A; Bases R; Seeliger MA; Tsirka SE
    J Pharmacol Exp Ther; 2024 Mar; 389(1):51-60. PubMed ID: 38296645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.